The upper bound of a 95 % confidence interval for the difference in prevalence of Stage 1 and 2 HTN between study arms indicates that discontinuation of study medication is unlikely to be associated with an increase in Stage 1 HTN of > 4.8 percentage points and in Stage 2 HTN of no > 5.8 percentage points .